Efficacy and safety of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy

Patients with intrahepatic cholestasis of pregnancy (ICP) benefit from ursodeoxycholic acid (UDCA) treatment. Since there is still certain reluctance to use UDCA in pregnant women, mainly due to warnings in the official SPC information in respective drug leaflets, our objective was to assess the eff...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hepatology 2016-09, Vol.15 (5), p.757-761
Main Authors: Parízek, Antonin, Šimják, Patrik, Cerný, Andrej, Šestinová, Alena, Zdenková, Anna, Hill, Martin, Dušková, Michaela, Procházka, Martin, Vlk, Radovan, Kokrdová, Zuzana, Koucký, Michal, Vitek, Libor
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with intrahepatic cholestasis of pregnancy (ICP) benefit from ursodeoxycholic acid (UDCA) treatment. Since there is still certain reluctance to use UDCA in pregnant women, mainly due to warnings in the official SPC information in respective drug leaflets, our objective was to assess the efficacy and safety of UDCA during pregnancy. Our retrospective multicentric study was performed on 191 consecutive pregnant women with ICP treated with UDCA. Any maternal and/or fetal complications of the UDCA treatment were searched for; healthy pregnant women (n = 256) served as controls. The UDCA treatment improved liver disease status in the majority of the affected women (86.1%). This treatment was well tolerated, with only negligible skin reactions (0.5%) and mild diarrhea (4.7%). No complications attributable to UDCA treatment were detected during the fetal life, delivery, or the early neonatal period. We confirmed the good efficacy and safety of UDCA treatment in pregnancy for both mothers and fetuses/neonates.
ISSN:1665-2681
DOI:10.5604/16652681.1212562